Voyager Therapeutics Announces Preclinical Data for Huntington’s Disease and Amyotrophic Lateral Sclerosis Programs at the Congress of the European Society of Gene and Cell Therapy
October 16, 2018 07:03 ET
|
Voyager Therapeutics, Inc.
One-time delivery of VY-HTT01 for Huntington’s disease achieves significant reduction of HTT gene expression in deeper tissues and outer layers of the brain of large animals One-time delivery of...